Giovanni Di Veroli

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Opportunities for Quantitative Translational Modeling in Oncology	2020	James Yates Helen M. Byrne Sonya C. Chapman Tao Chen L. Cucurull-Sanchez Juan A. Delgado San Martin Giovanni Di Veroli Simon J. Dovedi Carina Dunlop R. Jena

Common Coauthors

Coauthor	Papers Together
Herbert Struemper	1
Antonio Ramos‐Montoya	1
Juan A. Delgado San Martin	1
James Yates	1
R. Jena	1
François Mercier	1
L. Cucurull-Sanchez	1
Duncan I. Jodrell	1
Simon J. Dovedi	1
Carina Dunlop	1
Helen M. Byrne	1
Tao Chen	1
Emma C. Martin	1
Paolo Vicini	1
Sonya C. Chapman	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Tumor growthin vivo and as multicellular spheroids compared by mathematical models	1994	Miljenko Marušic Željko Bajzer Stanimir Vuk‐Pavlović James P. Freyer	1
+ PDF Chat	Adaptive clinical trial designs for phase I cancer studies	2014	Oleksandr Sverdlov Weng Kee Wong Yevgen Ryeznik	1
+	Dissecting cancer through mathematics: from the cell to the animal model	2010	Helen M. Byrne	1
+	Optimizing Dosing of Oncology Drugs	2014	Lori M. Minasian Osnat Rosen Daniel Auclair Atiqur Rahman Richard Pazdur Richard L. Schilsky	1
+ PDF Chat	Adjusting overall survival for treatment switches: commonly used methods and practical application	2013	Claire Watkins Xin Huang Nicholas Latimer Yiyun Tang Elaine WRIGHT	1
+	Cell loss factors and the linear-quadratic model	1995	Bleddyn Jones Roger Dale	1
+ PDF Chat	Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents	2004	Monica Simeoni Paolo Magni Cristiano Cammia Giuseppe De Nicolao Valter Croci Enrico Pesenti Massimiliano Germani Italo Poggesi Maurizio Rocchetti	1
+	Determining the optimal dose in the development of anticancer agents	2014	Ron H.J. Mathijssen Alex Sparreboom Jaap Verweij	1
+	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor	2012	Harvey Wong Laurent Vernillet Amy Peterson Joseph A. Ware Lillian Lee Jean‐François Martini Peiwen Yu Congfen Li Geoffrey Del Rosario Edna F. Choo	1
+ PDF Chat	Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma	2015	Aziz Ouerdani Herbert Struemper A. Benjamin Suttle Danièle Ouellet Benjamin Ribba	1
+ PDF Chat	Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling	2009	Hermann B. Frieboes Mary E. Edgerton John P. Fruehauf Felicity R. A. J. Rose Lisa K. Worrall Robert A. Gatenby Mauro Ferrari Vittorio Cristini	1
+ PDF Chat	A Review of Mixed‐Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis	2014	Benjamin Ribba Nicholas H. G. Holford Paolo Magni Iñaki F. Trocóniz Ivelina Gueorguieva Pascal Girard Céline Sarr Moran Elishmereni Charlotte Kloft Lena E. Friberg	1
+ PDF Chat	Generalizing the TITE‐CRM to adapt for early‐ and late‐onset toxicities	2005	Thomas M. Braun	1
+ PDF Chat	Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy	2015	Feng Fu Martin A. Nowak Sebastian Bonhoeffer	1
+ PDF Chat	Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules	2014	Kevin Leder Kenneth L. Pitter Quincey LaPlant Dolores Hambardzumyan Brian D. Ross Timothy A. Chan Eric C. Holland Franziska Michor	1
+	Predicting the active doses in humans from animal studies: A novel approach in oncology	2007	Maria Teresa Rocchetti Monica Simeoni Enrico Pesenti Giuseppe De Nicolao Italo Poggesi	1
+	Non-invasive 3D time-of-flight imaging technique for tumour volume assessment in subcutaneous models	2014	Juan A. Delgado San Martin Philip Worthington JWT Yates	1
+ PDF Chat	Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals	2016	Emma C. Martin Leon Aarons James Yates	1
+ PDF Chat	Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations	2017	Moreno Ursino Sarah Zohar Frederike Lentz Corinne Alberti Tim Friede Nigel Stallard Emmanuelle Comets	1
+	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014)	2017	FT. Musuamba Efthymios Manolis Nicholas H. G. Holford S. Y. Amy Cheung Lena E. Friberg Kayode Ogungbenro Martin Posch JWT Yates Scott Berry Neal Thomas	1
+	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials	2018	Sirisha L. Mushti Flora Mulkey Rajeshwari Sridhara	1
+ PDF Chat	Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model	2018	Yuri Kosinsky Simon J. Dovedi Kirill Peskov Veronika Voronova Lulu Chu Helen Tomkinson Nidal Al‐Huniti Donald R. Stanski Gabriel Helmlinger	1
+ PDF Chat	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts	2018	Zinnia P. Parra‐Guillén Víctor Mangas‐Sanjuán Maria Garcia‐Cremades Iñaki F. Trocóniz Gary Mo Celine Pitou Philip W. Iversen Johan Wallin	1
+	Evaluation and translation of combination therapies in oncology – A quantitative approach	2018	Tim Cardilin J.O. Almquist Mats Jirstrand Johan Gabrielsson	1
+ PDF Chat	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors	2019	Anyue Yin Dirk Jan A. R. Moes J. G. Coen van Hasselt Jesse J. Swen Henk‐Jan Guchelaar	1
+ PDF Chat	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models	2019	René Bruno Dean Bottino Dinesh P. de Alwis Antonio Tito Fojo Jérémie Guedj Chao Liu Kristin R. Swanson Jenny Zheng Yanan Zheng Jin Y. Jin	1
+ PDF Chat	MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges	2020	Sriram Krishnaswami Daren Austin Oscar Della Pasqua Marc R. Gastonguay Jogarao Gobburu Piet H. van der Graaf Danièle Ouellet Stacey Tannenbaum Sandra A. G. Visser	1
+ PDF Chat	A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics	2020	Jiajie Yu Na Wang Matts Kågedal	1